Derma Sciences, Inc.
We actively develop, acquire, and market wound care products that exhibit innovative technologies, empower caregivers, and focus on the unmet needs of patients. As the science underlying the issues of chronic wounds advances, our goal is to be a leader in the development of active therapies.
Three significant new advanced wound care products offer unique therapeutic opportunities: MEDIHONEYÙ, ALGICELLÙ Ag, and the MOBILITY-1Ù device.
MEDIHONEYÙ Active Leptospermum Honey dressings:
MEDIHONEYÙ is the first honey-based product cleared for use by Health Canada and also the first cleared for use by the FDA. These unique dressings contain Active Leptospermum Honey, indigenous to New Zealand (Manuka) and Australia (Jellybush). The dressings can be used in all phases of wound healing and could be considered a key dressing in any wound bed preparation protocol. These qualities can help to take much of the guesswork out of wound management.
ALGICELLÙ Ag antimicrobial silver alginate dressing:
ALGICELLÙ delivers 1.4% ionic silver at a slow consistent release rate for strong broad-spectrum efficacy, has an optimal gelling profile, and superior absorption. Priced in-line with current reimbursement codes, caregivers can reach for this best-in-class dressing more often than other antimicrobial silver dressings, and achieve optimal economic and clinical outcomes.
MOBILITY-1Ù Intermittent Pneumatic Compression Device:
MOBILITY-1 is the only intermittent pneumatic compression device that allows mobility for patients who suffer from various disorder such as lymphedema or chronic venous insufficiency and want to continue to work, go on vacation, or simply live their normal daily life while receiving optimal therapy.
General: Barbara Benchoff
bbenchoff@dermasciences.com
1.609.514.4744
Votes:35
Comments: 0